Showing posts with label Tuberculosis statistics. Show all posts
Showing posts with label Tuberculosis statistics. Show all posts

Sunday, 27 November 2011

TUBERCULOSIS: Eurasia statistics

Christoph Hamelmann


The European/Central Asian region has the highest rate of multi-drug- and extensively-drug-resistant tuberculosis (MDR and XDR TB respectively, in practitioner’s jargon) in the world. According to WHO, there are currently an estimated 81,000 people with MDR or XDR TB in the region. Most of them do not receive a proper diagnosis and treatment.
At the national level, health systems often do not have enough capacity to identify and treat cases. The situation is further worsened by the substantial amount of (partially illegal) labor migration in the region. Moving to another country means that diagnoses get hidden or delayed and treatment interrupted.
Drug resistant TB is not purely a health issue. It has economic repercussions as well. Compare the costs of just a few Euro for a normal TB treatment course with thousands of Euro per person for all costs related to dealing with drug-resistant TB. WHO is estimating that we need to invest US $ 5.2 billion over the next 5 years for a reasonable action plan; without it, the final bill will be definitely larger.
Ultimately however at the core of this problem are social determinants of health and inequitable access to health services.
For the above reasons, I welcome next week’s high-level meeting on “Migration and tuberculosis: cross border care and control in Central Asia” in Almaty. I am looking forward to reviewing the outcomes of the meeting and, perhaps most importantly, to helping with the implementation plan coming out of the event. http://europeandcis.undp.org/blog/tag/tuberculosis/

Sunday, 6 March 2011

TUBERCULOSIS: Canada: TB deaths show need for housing solution

CBC News : Feb 21, 2011

The head of the Canadian Medical Association said cities need to do a better job providing sustainable housing if they want to lower mortality rates among homeless people with tuberculosis.


Inadequate housing complicates TB treatment. Inadequate housing complicates TB treatment. (Nathan Denette/Canadian Press)


Last week a study published in the journal Emerging Infectious Diseases found that 20 per cent of homeless people with tuberculosis die within a year of diagnosis.
The problem was identified ten years ago, say the study's Toronto-based authors, but the high mortality rate still hasn't changed.
An inquest into the death of Joseph Teigesser, a homeless man who died of tuberculosis in Toronto in 2001, had made 13 formal recommendations, including provincial funding for a centralized clinic system to provide specialized care for people with TB and improvements to shelter ventilation.
But the study's authors said those are two areas where the province and cities have fallen short.
CMA president Dr. Jeff Turnbull, who also serves as chief of staff for the Ottawa Hospital and co-founded the Ottawa Inner City Health program, said the study's bleak picture should push cities to spend more on sustainable and supportive housing.

Shelter improvements not enough: MD
He said improvements to shelters, however, wouldn't be enough to counter the underlying barriers to proper treatment of the disease, which primarily targets the lungs.
"Improving conditions in a shelter doesn't make a lot of sense to me," said Turnbull.
"I'd rather move people from a shelter into a much more appropriate setting where we can bring in better health services. Another part of it is improved education, screening and better management of tuberculosis when we do identify it in our homeless community," he said.
Turnbull said tuberculosis claimed Inuit artist Normee Ekoomiak in Ottawa two years ago.
Turnbull said Ekoomiak, who had been living in and out of homeless shelters for two decades, was "a perfect example of somebody who had tuberculosis and ... didn't get the treatment he deserved because he was homeless," he said.
"We shouldn't have people living in emergency shelters for the better part of their life. That's not best for anyone," said Turnbull.

Worldwide, tuberculosis claimed the lives of 1.7 million people in 2009, according to the World Health Organization.

http://www.cbc.ca/news/canada/toronto/story/2011/02/21/ottawa-tb-homeless-shelters.html

Monday, 21 February 2011

Drug-resistant M. tuberculosis more likely in foreign-born patients with TB Meningitis

 February 9, 2011

Vinnard C. Emerg Infect Dis. 2011; doi:10.3201/eid1703.101715.

Patients with tuberculosis meningitis born outside of the US were more likely to be infected with an isoniazid-resistant strain of Mycobacterium tuberculosis when compared with US-born patients, according to new findings from a cross-sectional study.
Christopher Vinnard, MD, of the division of infectious diseases at the University of Pennsylvania School of Medicine, and colleagues pooled data on tuberculosis meningitis cases between 1993 and 2005 from the US National Tuberculosis Surveillance System and assessed patient characteristics associated with isoniazid resistance.
Patients with a previous diagnosis of TB or with multidrug-resistant disease were excluded from the study.
Of 1,649 patients with tuberculosis meningitis, 14% were infected with isolates resistant to isoniazid, rifampin, ethambutol, pyrazinamide, or streptomycin — 8% were infected with at least one isoniazid-resistant isolate. Isoniazid-resistance was uncommon in patients aged older than 64 years.
Foreign birth was the only characteristic independently associated with isoniazid-resistance on initial testing (OR=2.53; 95% CI, 1.66–3.88). Twenty of the 69 foreign-born patients with isoniazid-resistant disease resided in Mexico; seven of the nine countries with 2 or more cases of isoniazid-resistant disease were located in Asia. Although 53% of patients were HIV-positive, no association was observed between HIV and isoniazid resistance (OR=1.10; 95% CI, 0.70-3.65).
“Prospective studies are needed to determine whether individual patient characteristics can guide the selection of tuberculosis meningitis therapies and lead to an improvement in clinical outcomes,” the researchers wrote.
http://infectiousdiseasenews.com/article/80361.aspx

TUBERCULOSIS: Sri Lanka: Over 11,000 Tuberculosis patients annually

Nadira GUNATILLEKE
Every year around 11,000 new Tuberculosis (TB) patients are discovered and 2,000 of them are from Colombo. Out of this number, 1,000 are detected from the Colombo Municipality, Health Minister Maithripala Sirisena said.
Addressing the gathering after opening a Direct Observation Treatment Centre (DOT) at Asiri Hospital, Colombo yesterday Minister Sirisena said the rapidly increasing population in the Colombo city, environmental pollution, and similar reasons are behind the increasing number of TB patients in the Colombo city. In the early nineties, TB was a scary disease that could not be cured. But now TB can be completely cured within six months with proper treatment.
Minister Sirisena pointed out that private and public sectors should join hands to deliver a better service to the public. President Mahinda Rajapaksa's Government always promotes the partnership between State and private sector. A healthy society can be created with the participation of both the State and private sector.
People like to visit private hospitals when they are concerned about their privacy and the confidentiality. Therefore they like to get treatment for TB from private hospitals than State hospitals.
Health Ministry officials, representatives and staff of Asiri Hospital and many others were present.
http://www.dailynews.lk/2011/02/10/news34.asp

Wednesday, 2 February 2011

TUBERCULOSIS: Promising New Approach to a TB Vaccine (H56)

Jan. 25, 2011
C Aagaard et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nature Medicine. DOI: 10.1038/nm.2285 (2011).


A team of European and U.S. researchers have found that a new vaccine strategy tested in mice provides improved protection from tuberculosis (TB) infection than the vaccine currently used in humans, known as BCG. Their findings were published online on January 23rd in the journal Nature Medicine.
Led by scientists at the Statens Serum Institut (SSI) in Denmark, the study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation. The NIAID support was through the TB Vaccine Testing and Research Materials program at Colorado State University, an initiative to speed the development of new TB vaccines and treatments.
Caused by the bacterium Mycobacterium tuberculosis (Mtb), TB remains one of the major causes of disability and death worldwide, with an estimated 1.7 million deaths in 2009 and increasing rates of drug-resistant disease. The BCG vaccine, the only one approved for human use, provides limited protection against immediate TB illness but does not prevent reactivation of latent infection, in which Mtb persists in human cells for years and may later develop into active disease.
In this study, researchers at SSI combined two proteins that had previously been tested with a new component, a stress response protein that Mtb produces during latent infection. This three-component vaccine, known as H56, was administered to uninfected mice before and after Mtb infection. The multistage vaccine not only protected against initial illness, but controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively than BCG alone. Because of the success of this study, the vaccine candidate is now entering clinical development.

Christine Sizemore, Ph.D., chief of the Tuberculosis, Leprosy and other Mycobacterial Diseases Section at NIAID, is available to comment on this article. To schedule interviews, please contact Nalini Padmanabhan, 301-402-1663, niaidnews@niaid.nih.gov.
http://www.niaid.nih.gov/news/newsreleases/2011/Pages/TBvaccineCollaboration.aspx

Monday, 31 January 2011

TUBERCULOSIS: Limited diagnostic resources

In 2009, 1.7 million people died from tuberculosis (TB)—equating to 4,700 deaths a day—including 380,000 people living with HIV. TB remains the most common cause of death in people living with HIV and compared to people without HIV, people living with HIV are more than 20 times more likely to develop TB. Furthermore, TB infection may occur at any stage of HIV disease and is often the initial presentation of underlying HIV infection. Without antiretroviral treatment, up to 50% of people living with HIV who are diagnosed with TB die during the 6–8 months of TB treatment.

Although antiretroviral treatment can reduce the incidence of TB both at the individual and population level, people living with HIV on antiretroviral treatment still have higher TB incidence rates and a higher risk of dying from TB. Therefore, the World Health Organization recommends regular screening for active TB disease in all people living with HIV, so those identified as having active TB disease can be provided with appropriate treatment, and isoniazid preventive therapy (to help mitigate TB morbidity, mortality, and transmission) can be given to vulnerable individuals who do not yet have active TB.

Why Was This Study Done?
There is currently no internationally accepted evidence-based tool to screen for TB in people living with HIV—a serious gap given that the presenting signs and symptoms of TB in people living with HIV are different from those in people without HIV. Therefore, the researchers aimed to develop a simple, standardized TB screening rule for resource-constrained settings, on the basis of the best available evidence that would adequately distinguish between people living with HIV who are very unlikely to have TB from those who require further investigation for TB disease.

What Did the Researchers Do and Find?
The researchers selected 12 studies that met their strict criteria, then asked the authors of these studies for primary data so that they could map individual-level data to identify five symptoms common to most studies. Using a statistical model, the researchers devised 23 screening rules derived from these five symptoms and used meta-analysis methods (bivariate random-effects meta-analysis) and the association of study-level and individual-level correlates (hierarchical summary relative operating characteristic curves) to evaluate the sensitivity and specificity of each tool used in each individual study.
The authors of the selected studies were able to provide data for 29,523 participants, of whom 10,057 were people living with HIV. The dataset included 9,626 people living with HIV who had TB screening and sputum culture performed, of which 8,148 individuals could be evaluated on the five symptoms of interest from nine of 12 studies. TB disease was diagnosed in 5.8% of people living with HIV and the best performing rule was the presence of any one of the following: current cough (any duration), fever, night sweats, or weight loss. The overall sensitivity of the rule was 78.9% and the specificity was 49.6%. However, the sensitivity of the rule increased to 90.1% among participants selected from clinical settings and to 88.0% among those who were not previously screened for TB.

What Do These Findings Mean?
The results of this study suggest that in resource-constrained settings, the absence of current cough, fever, night sweats, and weight loss (all inclusive) can identify those people living with HIV who have a low probability of having TB disease. Furthermore, any one of these symptoms can be used in resource-constrained settings to identify people living with HIV who are in need of further diagnostic assessment for TB.
Despite the limitations of the methodology used in this study, until there are evidence-based and internationally recommended guidelines for the diagnosis and treatment of TB in people living with HIV, use of the algorithm developed and presented in this study could result in earlier TB diagnosis and treatment for people living with HIV and could help to substantially scale-up isoniazid preventive therapy
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000391

TUBERCULOSIS: ‘7,000 Nigerians have drug-resistant TB’

Sade Oguntola : 27 January 2011
National Coordinator, National Tuberculosis and Leprosy Control Programme, Dr Mansur Kabir said at least 7,000 Nigerians had contracted a form of Tuberculosis (TB) that does not respond to the usual drugs for treating TB.


Dr Kabir stated this during a 2-day national training for doctors, nurses and general health workers on clinical and programmatic management of Multidrug Resistant Tuberculosis (MDR-TB), held in Ibadan.
Dr Kabir declared that many patients were discovered to have developed the MDR-TB in a survey being undertaken in the country, thus the Ministry becoming actively involved in ensuring increased access to treatment for MDR-TB.
According to him, “with the support of partners like USAID and CDC, we are working assiduously to improve our diagnostic capacity, to identify patients with MDR-TB as well as ensure the availability of required drugs for their treatment.”
Dr Kabir, disclosing that only one centre at University College Hospital (UCH), Ibadan, was treating MDR-TB cases, stated that more centres were expected to start operation in Calabar, Lagos, Zaria and Kano before the end of 2012.
He attributed the delay in commencement of treatment for MDR-TB at other zones of the country to the difficult nature of diagnosing and treating this form of TB, its expensive cost as well as the required expertise to man such facilities.
Dr Kabir, while expressing his displeasure on people selling anti-TB drugs that were meant to be free, stated that the Health Minister, Professor Onyebuchi Chukwu had written to the Inspector of police in order that punitive measures might be taken on the issue.
While declaring that Private-Public-Partnership was important in ensuring all cases of TB receive adequate care, he solicited for better documentation of TB distribution at the local government levels and health facilities to ensure adequate care is available for TB.
Dr Kabir advised persons with TB to ensure they adhere to their treatment while individuals protect themselves from contracting TB by living in well ventilated rooms, eating good diet, seeking medical care when coughing, shun smoking, maintain good hygiene as well as ensure that all babies receive the BCG vaccine to protect them from TB.
Currently, about 500,000 cases of MDR-TB cases occur yearly in the world and about 3 per cent are properly treated because diagnosis of MRD-TB is new and the required drugs are expensive.
Nigeria has the highest case of TB in Africa and it is estimated that about 450,000 new cases of TB occur yearly in Nigeria. However, only 94,000 of these TB cases were detected last year. Children and pregnant women are more vulnerable to contracting TB because of their immunity level.
http://tribune.com.ng/index.php/health-news/16707-7000-nigerians-have-difficulty-treating-tb-

TUBERCULOSIS: Mozambique's new lab

Maputo — Mozambican Health Minister Alexandre Manguele on Wednesday re-inaugurated the country's main tuberculosis laboratory, remodelled and equipped with funding of over 1.5 million US dollars, provided by the United States Agency for International Development (USAID).

The National Tuberculosis Reference Laboratory is located within the grounds of Maputo Central Hospital, and is now equipped with the most recent technology for diagnosing tuberculosis, including drug resistant tuberculosis.
Speaking during the inauguration ceremony, Manguele said the laboratory will undertake specialist and reference diagnoses, and provide continual education for laboratory technicians. It will ensure quality control for microscope diagnosis, and surveillance for multi-drug resistant strains of the disease.
"Making this laboratory operational is a further determinant step for ensuring that the country's health policies are based on evidence generated nationally", he added.
Manguele warned that, in order to ensure sustainable growth in laboratory activities in Mozambique over the coming years, the country needs continual investments in human resources, equipment, up-to-date technologies, infrastructures and systems.
It was immediately necessary, he said, to strengthen the team working at the national reference laboratory, and to ensure regional tuberculosis laboratories in Beira and Nampula became operational,
The rate of prevalence of tuberculosis in Mozambique is 504 cases per 100,000 inhabitants, and Mozambique is in 19th position in the 22 countries that still have a high tuberculosis burden.
Data from 2007/2008 indicate that 3.5 per cent of new tuberculosis cases in Mozambique are caused by the multi-drug resistant strains of the bacterium. "To these statistics, which are alarming enough in themselves, we must add the fact that the tuberculosis epidemic runs in tandem with the HIV epidemic", said Manguele. "The association between HIV and tuberculosis has already become one of the major challenges for public health in southern Africa".
For his part, Todd Amani, Director of the USAID office in Mozambique, said he hoped the laboratory would contribute to improving the provision of public health services.
"Strengthening institutions such as the National Tuberculosis Reference Laboratory will help improve the prevention, diagnosis and treatment of tuberculosis, and increase the links from home care to hospital care, thus reducing the mortality and morbidity caused by tuberculosis, HIV/AIDS and other related diseases", said Amani.
http://allafrica.com/stories/201101270178.html

Sunday, 23 January 2011

TUBERCULOSIS: vaccine protects before and after exposure

23 January 2011


A new vaccine that can fight tuberculosis (TB) before and after infection has been developed by Danish scientists.
It could offer protection for many years more than is now possible.
TB is a huge global problem, particularly in developing countries, where access to antibiotics to treat the disease is limited.
The latest vaccine, so far tested in animals, is featured in the journal Nature Medicine.
TB is a disease of the lungs, causing symptoms such as coughing, chest pains and weight loss. Untreated, it can be deadly.
However, only in a small number of cases - fewer than 5% - do the symptoms develop immediately after infection.
In more than 90% of cases, once Mycobacterium tuberculosis, the bacterium which causes the disease, has invaded the body it changes its chemical signature, and lives in a dormant - or "latent" - state.
Usually the bacterium never emerges from this latent state, but in around 10% of cases it reactivates - often years or even decades later - to trigger severe symptoms.
Current vaccines, such as the BCG vaccine, work only if given before exposure to the bacterium.
They do not prevent infection, but do prevent acute symptoms and disease from emerging.
But once the bacterium has changed into its latent form it is effectively immune to the vaccine, and can bide its time, reactivating after the vaccine has ceased to have a preventative effect.
If successful in human trials, the new vaccine would be able to tackle that problem.

'Major breakthrough'
Developed by a team at the Statens Serum Institute in Copenhagen, it combines proteins that trigger an immune response to both the active and latent forms of Mycobacterium.
Researcher Professor Peter Lawætz Andersen said: "It might be possible to give a booster jab post-exposure to older children or even young adults which would protect them well into adulthood."
Although TB can be treated with antibiotics, those drugs are often not easily accessible in the developing world, where the new vaccine could have the greatest benefit.
Professor Andersen said: "In these areas you cannot go in and treat more than half the local population. For instance, in Capetown 60% of people are thought to be infected."
Professor Peter Davies, secretary of the group TB Alert, said: "A vaccine which can both protect against initial infection and protect from a breakdown of infection into disease is a major breakthrough.
"One of the main disadvantages of BCG was that it could only prevent infection going on to disease in the initially uninfected individual. It was therefore of no use in protecting infected adults who would become an infectious source of disease. Protecting children, though of value, does not protect against transmission, as children with active disease do not usually transmit disease.
"So far so good but we must remember that mice are not men (or women)."
Professor Francis Drobniewski, Director of the Health Protection Agency's National Mycobacterium Reference Laboratory said: "This is an exciting and thoughtful piece of research. The existing BCG vaccine is cheap, safe, widely used but of limited efficacy.
"With over nine million new TB cases globally each year and increasing levels of drug resistance new diagnostics, drugs and especially effective vaccines are desperately needed."

UK situation
The number of tuberculosis cases in the UK topped 9,000 in 2009 - the highest for nearly 30 years.
Diagnoses have been rising almost continuously since the 1980s, with many of the new cases thought to be among people who caught the disease abroad.
There has also been a sharp rise in drug-resistant TB cases.
The Health Protection Agency has warned more efforts must be made to curb the problem.

http://www.bbc.co.uk/news/health-12224172

Tuesday, 18 January 2011

TUBERCULOSIS: Childhood tuberculosis: addressing a forgotten crisis

14 January 2011
Of the 9 million estimated cases of tuberculosis (TB) each year, at least 10 to 15 percent occur in children. Yet the problem is dangerously neglected, because most diagnostic tests are not designed for children.
The magnitude of this neglected public health problem is highlighted in a letter published in the New England Journal of Medicine this week by a TDR-led group of experts on paediatric TB. The team has joined forces with the Stop TB Partnership's Childhood TB subgroup, the World Health Organization's Stop TB Department and other international experts on paediatric TB to promote the adoption of a common reference standard for the evaluation of new TB diagnostics in children.
While new breakthrough diagnostic tests for TB are being developed, including one endorsed by WHO in December, the advances highlight a significant gap in TB research generally: the paucity of diagnostic research and of reliable diagnostic tools for TB in children. Historically, children have received a lower priority than adults in TB control efforts because they are both considered less infectious and are more difficult to diagnose.
Because their symptoms are different to the classic chronic cough of TB in adults, children usually go to a children's health service or a general clinic rather than a TB diagnostic centre. The result is that many cases go undiagnosed or are diagnosed incorrectly, so that children are more likely to rapidly progress to a severe state such as TB meningitis, which has harmful long term effects and high mortality.
"Our ability to even assess the magnitude of the problem is severely hampered by the lack of diagnostics in children," said Dr. Luis Cuevas, a scientist from TDR's diagnostics team. The problem is that TB diagnostic tools, both currently and in development, do not adequately take into account the special requirements for assessing children, he said. Cuevas is the author of a recent paper focusing on the problem.
"While there are a lot of promising diagnostic tools in the works, there is a need for increased support from international organizations and funders to promote the development of new diagnostics that are suitable for TB in children," said Cuevas. The common reference standard being prepared by the team of paediatric TB experts provides guidelines for paediatric testing of new diagnostic tools, specimen sampling methods, and comparative testing in different country settings. Further work to develop standardized methods to evaluate new TB diagnostics in children is currently under way.
The authors of the original NEJM article, Boehme et al., replied that they "can only agree that additional studies in children are a priority."
TDR's coordinator for research on neglected priorities, Soumya Swaminathan, is guest editor of a special issue on TB in children for The Indian Journal of Paediatrics. Next March, a conference will be held in Stockholm to advocate for research on paediatric TB, and in June the U.S. National Institutes of Health will hold a meeting to set a standard method for evaluating new diagnostics for children.
http://apps.who.int/tdr/svc/news-events/news/paediatric-tb

Sunday, 9 January 2011

TUBERCULOSIS: WHO recommends against inaccurate tuberculosis tests

The Lancet,  8 January 2011 : Original Text Kelly Morris

Misleading serology tests for tuberculosis could be worsening the epidemic in some high-burden countries. WHO will be issuing policy advice against their use in early 2011.
Although no international guideline recommends their use, scores of commercial serology tests for tuberculosis are being sold in high-burden countries. Some are laboratory-based tests, whereas others are rapid dipstick tests, which could fill a vital niche for a point-of-care tuberculosis diagnostic test. “If they worked, the problem of a gap in the pipeline for a point-of-care assay would have been solved decades ago”, comments Madhukar Pai, co-chair of the STOP-TB Partnership's new diagnostics working group. “The pity is that they don't work. In fact, they're inaccurate and useless.”
WHO is due to release a negative policy recommendation—the first of its kind for the organisation—on current commercial tuberculosis serodiagnostics. Results of several meta-analyses have indicated poor performance of these tests, and in 2008, an assessment of 19 commercial assays by TDR—the UN special programme for research and training in tropical diseases—found that none of the assays were good enough to replace sputum microscopy or as an add-on test to rule out tuberculosis. Manufacturers continue to claim that their tests are effective and fill a diagnostic niche, especially in sputum smear-negative patient groups.Karin Weyer, WHO coordinator of TB diagnostics and laboratory strengthening, told The Lancet that “the negative policy process is a new concept in WHO”. But, she says, the process has been identical to that for positive recommendations, such as the endorsement announced on Dec 8 of a fully automated nucleic-acid amplification test (Xpert MTB/RIF, Cepheid) to improve tuberculosis diagnosis.
The available evidence on serodiagnostic kits has now been rigorously assessed, including meta-analyses when appropriate, and reviewed by an independent WHO expert group, says Weyer. “The expert group endorsed the findings from an updated systematic review since the TDR report in 2008 and essentially concluded that we should proceed with negative policy guidance based on the fact that the performance characteristics of these tests were way below what one would want and also because the quality of the data were so weak and so bad that it warranted a recommendation against the use of these tests”, she explains.
“Everyone is aware of the consequences of bad drugs and vaccines, but nobody really thinks about bad diagnostics and what impact they can have”, comments Pai. In their report, released at the end of December, the WHO Strategic and Technical Advisory Group for TB acknowledges “the adverse impact of misdiagnosis and wasted resources on patients and health services when using these tests for the diagnosis of active TB”, and recommends WHO to proceed with written guidance advising against current serodiagnostic kits. Further targeted research is strongly recommended since potential exists for research to develop accurate serologic assays, which could fill the point-of-care niche. WHO is being careful with preparation of the negative policy so as not to stifle innovation and research investment in tuberculosis diagnostics, says Weyer.
Commercial serodiagnostic kits are widely available, but the problem is probably greatest in India, where Pai estimates that serodiagnostic kits are used on at least 1·5 million people with suspected tuberculosis every year. Such testing is not done through the Revised National TB Control Programme (RNTCP) but through the unregulated private sector, which manages a substantial proportion of tuberculosis cases. Patients pay for serodiagnostic kits, and the market is estimated conservatively at over $US15 million in India alone, compared with $65 million for the entire RNTCP.
Despite country-wide DOTS coverage by the RNTCP, India continues to have more than 2 million new cases of tuberculosis every year. Ongoing transmission will not be reduced without intensified early case detection, which first relies on access to quality diagnosis. Writing in The New Yorker on Nov 15, journalist Michael Specter described how, in India, “for most patients, the choices are bleak”—overcrowded public hospitals versus unreliable tests at unregulated private laboratories or clinics.
Everyone in the private-sector chain gets a cut of patient fees—up to $10—30 per serodiagnostic kit—especially the referring doctors and private clinicians, who are often the same individual, Specter reports. Financial incentives perpetuate this system, Pai explains, since: “a private practitioner may not order sputum microscopy because you don't make much money out of a cheap test like sputum smears. The more expensive the test ordered, the more money you get back”, he explains.
The available evidence indicates that current tests lack either the necessary sensitivity or specificity or both to be an effective diagnostic test, and for many of these tests, false results far outnumber true results. Low sensitivity means increased false-negative results, which increase morbidity, mortality, and ongoing transmission of tuberculosis. Low specificity means more false-positive results; patients might then be given 6 months of potentially toxic treatment, while their underlying pathology remains uninvestigated and undiagnosed.

Click to toggle image size Atul Loke/Panos
India has more than 2 million new cases of tuberculosis every year

Many commercial tuberculosis serology kits are manufactured in China or India, but some are from western countries, such as France, the UK, Canada, and the USA. These manufacturers are selling high volumes of their test kits in countries such as India, although their tests are not licensed or used in the countries that make them.
During WHO's systematic review process, says Weyer, “we quickly discovered that manufacturers of these commercial serodiagnostics simply change the name of the test frequently and re-market and re-sell the same test under a new brand name. So, teasing out which test belonged to which brand name and updating the previous review by TDR proved to be a real challenge, as we wanted to be as solid as we could possibly be on the actual evidence.”
The key question is how much will the WHO guidance affect the sale and use of these tests in the private sector? “The ideal is that the public sector would be attractive enough and use state-of-the-art new tests, so that patients don't feel that they need to go to the private sector to get what they think may be a better diagnosis”, says Weyer.
However, given the extent of private-sector medicine, the concept of public—private mix (PPM) is being hailed in some quarters as the key to increasing efforts to tackle tuberculosis. The final report of WHO's subgroup on PPM for tuberculosis care and control advised earlier this year that countries need to scale up PPM, and involve provider groups outside national programmes to develop national strategic plans. Recommended approaches also include certification and accreditation of care providers and laboratories, and a system for mandatory notification of tuberculosis.
To achieve PPM recommendations, regulation of private-sector medicine will need to be developed and implemented in high-burden countries. What is absent from the PPM report is recognition that regulatory frameworks for diagnostic tests are also often weak or non-existent. WHO is helping countries establish regulatory systems to review the local relevance of diagnostics, and determine whether such tests should be marketed and sold, says Weyer. But, she foresees “a long-term difficult process”, as local expertise and capacity are often limited and regulatory frameworks need to be drawn up and passed through national legal systems country by country.
“Public-private partnership is the way to go”, asserts Camilla Rodrigues, a physician at the private Hinduja Hospital, in Mumbai, India, who has trialled the Xpert MTB/RIF system for diagnosis and drug-resistance testing of tuberculosis for more than 3 years. Rodrigues would like to see physician education on the unreliability of serology in endemic regions and laboratory accreditation encouraged. National governments need to provide guidelines for tuberculosis testing with “strict regulation in place for defaulters”, she says, adding that laboratories need diagnostic algorithms and strengthened capacity both for gold-standard tests, such as culture, and validated new molecular tests.
Weyer agrees, but notes that: “PPM alone will not overcome barriers presented by the lack of country regulatory frameworks for new diagnostics”. Nevertheless, market forces could play a part in developing and implementing better tuberculosis diagnostics. If Xpert MTB/RIF or other technologies are developed to become point-of-care tests, the private sector already has the infrastructure to deliver, and effective diagnostics could successfully replace inaccurate tests, says Pai.
The chief executive of a large private Indian diagnostic laboratory chain, Sanjeev Chaudhry, told The Lancet that Super Religare Laboratories strongly concurs in discouraging use of serodiagnostic kits in Indian settings. However, mere policy change might not be effective with the current magnitude of the challenge, he says, so, “instead of change in policy by private lab(s) in isolation or even as a consortium, we seriously feel that collective and dedicated efforts are required equally by the public- and private-sector service providers”.
As pathology service providers are expected to offer and satisfy the needs of the market, Chaudry continues that “we need to have an alternative cost-effective option along with appropriate awareness among clinicians and doctors”. Rodrigues notes that “the Indian diagnostic market is thriving. There is certainly potential for low-cost, accurate, and newer tests to be produced in India which will lower the cost.”
WHO guidance will be very clear, Weyer confirms, “to reflect the current commercial serodiagnostic tests but not to jeopardise future research and new antigen and biomarker discovery programmes that would guide and inform the development of point-of-care tests”.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960005-6/fulltext?rss=yes

TUBERCULOSIS: Getting a Clearer Picture of Tuberculosis in Pakistan

06 January 2011
By Carrie Loewenthal Massey



Stephen Engelken and Makhdoom Shahabuddin standing together (State Dept.)  In Islamabad, U.S. Deputy Chief of Mission Stephen Engelken and Pakistan Minister of Health Makhdoom Shahabuddin helped announce a new tuberculosis survey.

Pakistan long has been listed among the 22 nations with the highest rates of tuberculosis (TB). But precisely how high? The United States is partnering with Pakistan’s Ministry of Health and others to get the clearest answer to that question in decades.
With U.S. support, researchers are conducting the first comprehensive survey of TB in Pakistan since the 1980s and will generate data crucial to the Pakistani government’s ability to make informed decisions about public health.
“Having this information will allow both the public and private health service delivery sectors to be more responsive to the TB needs of the country,” said Dr. Sardar Talat Mahmud, senior health adviser with the U.S. Agency for International Development (USAID), via e-mail from Pakistan.
“An accurate understanding of the disease burden of a country is a critical component for planning and resource allocation by policy makers, managers and health practitioners,” he added.
The U.S. Embassy in Islamabad announced a $4.5 million grant from USAID in December to support the survey. The Dutch Tuberculosis Foundation is facilitating the research, and other partners include the World Health Organization (WHO); Paris-based nonprofit International Union against Tuberculosis and Lung Disease; and Management Sciences for Health, a U.S.-based international nonprofit organization.
“This survey is going to provide us with evidence to understand the magnitude of tuberculosis in Pakistan so we can plan effectively control of the disease,” Pakistani Minister for Health Makhdoom Shahabuddin said at the December 2010 announcement.
The United States and Pakistan are working on several joint health projects as part of the U.S.-Pakistan Strategic Dialogue, which also includes partnerships in energy, agriculture, defense, education, water and communications, among others.
“Our commitment to partner with Pakistani health officials and work together in areas they identify is part of America’s comprehensive commitment to improve the well-being of ordinary Pakistanis in tangible ways,” U.S. Deputy Chief of Mission Stephen Engelken said at the December 2010 grant announcement.
Already at work in the field, Talat and his colleagues started the survey in December 2010 and expect to complete it within 12 months. Using a short questionnaire and a chest X-ray, they will screen for TB symptoms in more than 150,000 adults — people over 15 years old — in 95 locations throughout Pakistan. The survey is one of the largest of its kind ever conducted, according to an embassy press release.
The survey results will replace outdated estimates of Pakistan’s TB burden, provide a more precise picture of the TB burden within the adult population and help Pakistan’s health sector better assess the annual risk of TB infection. Current TB incidence rates in Pakistan are based on computer modeling and a survey conducted in 1987; that makes it difficult for the Pakistani government to accurately measure its progress in the fight against TB, Talat said.
The survey is off to a productive start. According to preliminary reports Talat has received, “field work has been going very well and the community response has been very encouraging.”
While the data will support long-term public health decisions, the effort also has an immediate positive effect on the population’s well-being.
“Everyone who tests positive for TB is then referred to the nearest health facility for appropriate follow up and treatment,” Talat said.
TUBERCULOSIS IN PAKISTAN
With more than 413,000 new TB cases reported each year, Pakistan ranks eighth among the world’s 22 most highly TB-burdened countries, according to WHO. TB kills an estimated 48,000 Pakistanis each year.
Compounding the issue, multidrug-resistant TB struck Pakistan 13,000 times in 2009. (Multidrug resistant TB is a deadlier form of the disease where the majority of available TB drugs are ineffective.) WHO ranks Pakistan sixth of 27 countries battling multidrug-resistant TB.
The U.S. government has worked with Pakistan for many years to help control the spread of infection. USAID began supporting Pakistan’s effort to combat TB in 2003, primarily by providing assistance to the Pakistani government’s National Tuberculosis Control Programme, Talat said.
Pakistan also receives approximately $202 million in additional TB resources from the Global Fund to Fight AIDS, Tuberculosis and Malaria, to which the United States is the largest contributor.

A DEVASTATING GLOBAL HEALTH CRISIS
TB infects an estimated one-third of the global population, and approximately 1.7 million people worldwide died from the disease in 2009, according to Talat. It spreads easily through the air, and a contagious person can infect 10 to 15 people every year. People living in close quarters with others become especially vulnerable.
Several agencies within the U.S. government work to fight TB. In 2008, the National Institutes of Health (NIH) spent about $160 million on TB research, and ongoing NIH efforts complement those by the Centers for Disease Control and Prevention, the National Institute for Allergy and Infectious Diseases, and USAID.
“USAID has provided approximately $953 million through direct programs to improve TB services and prevent the spread of TB and multidrug-resistant TB in over 40 countries,” Talat said.
http://www.america.gov/st/develop-english/2011/January/20110106161915eirrac0.5755884.html?CP.rss=true

Monday, 3 January 2011

TUBERCULOSIS: The Fight to control tuberculosis in El Paso Mexican border

December 23rd, 2010
The daily crossings by both Texan and Mexican citizens to visit family, shop, and work open great risks in the transmission of infectious tuberculosis (TB). These crossings greatly affect the Texas-Mexico border, and in 2009, a total of 1,501 cases of TB were reported to the Texas Department of State Health Services.
A CDC public health advisor known as Bruce Health reported a case of drug resistant TB on a foreign national that crossed the border numerous times while in an infectious state. A “be on the lookout,” alert was issued by the El Paso Quarantine Station in April 16, 2007, for a Mexican national who had a very resistant strain of tuberculosis.
The patient was first diagnosed with TB in 2001 by Mexican health officials and treated with the drug, Rifater. The patient disappeared from the health system, and since the drug Rifater can be purchased over the counter in Mexico, he only took the drug when symptoms reappeared. The patient was not seen again until January 2007 when he visited the Mexican health department, and was again symptomatic.
The Juarez program started the patient on a 4 drug therapy in January 2007, and also placed the patient in a Directly Observed Therapy (DOT) program, which they never did before. The patient became multi-drug resistant (MDR).
A communication door was opened between the patient, Juntos program which provides support to the Juarez program by processing cultures, the medical director of the El Paso Quarantine Station, and the chief of the Juarez Health department, to advice the patient against crossing the U.S. border, traveling by air, and to gather information to conduct an investigation. He did not follow instructions and continued to cross the border.
The patient was then placed on a “Do not board “ list after much discussion with representatives from the Texas TB program, the Department of Homeland Security, Customs and Border Protection, the U.S. Department of State, and the Centers for disease Control. He voluntarily handed his visa to the U.S. Department of State.
An understanding between the patient and the U.S. Department of State was undertaken in which the patient would not legally travel to the United States, and his visa would not be revoked.
http://www.examiner.com/infectious-disease-in-el-paso/the-fight-to-control-tuberculosis-el-paso-mexican-border
 

Saturday, 18 December 2010

TUBERCULOSIS: US Health Officials Worry About TB in Mexico

CHIAPAS, Mexico (July 7) -- Tuberculosis, one of the world's deadliest diseases, has long been forgotten by most Americans, but it is re-emerging in a new, virulent form around the world. U.S. health officials now worry that especially dangerous strains of the airborne pathogen have surfaced in Mexico, thanks to a dysfunctional health care system in the country's poorest regions. And they could spread to the United States.
Here's one scenario that keeps health officials on edge: A Mexican contracts the disease from a family member, or even a poorly run hospital, and then comes to the United States seeking work. There, living in crowded, cramped conditions without adequate ventilation, he passes it to several other migrants. But instead of promptly seeking medical assistance, the workers shun health care out of fear that they won't be treated or risk being deported. As a result, the disease festers and spreads.
Dr. Eugene McCray, the chief of the international tuberculosis elimination program at the U.S. Centers for Disease Control and Prevention, considers any legal barriers to care "abysmal, because people are in the community and they are going to transmit disease and it is going to affect Americans. It is very short-sighted." He said the best way to halt the disease isn't border protection, but increased collaboration and support to strengthen Mexico's health system. "For enlightened self-interest, we need to be concerned about tuberculosis," he said. "It has been totally ignored for many, many years."
Tuberculosis is a disease of poverty, exacerbated through crowded, dank living conditions and inadequate medical care. When the disease is not treated promptly and aggressively, it can easily pass between people living in close quarters, such as prisoners, refugees, migrant workers and their family members. Over the last decade, poor treatment has contributed to the growth of multidrug resistant (MDR) and extensively drug resistant (XDR) strains of TB, which are more deadly and far more stubborn than older strains.
"Unless the fundamental causes of MDR TB and XDR TB are addressed in the United States and internationally, the United States is likely to experience a growing number of cases ... that will be difficult, if not impossible, to treat or prevent," according to a 2009 report from the CDC.
The story of Marcela Gomez Vasquez and her family illustrates what can happen when proper treatment procedures are not followed. She lives with her six children in a mountain village of Chiapas, Mexico's southernmost state. The 44-year-old, a member of the indigenous Tzotzil community who speaks only cursory Spanish, contracted TB several years ago. She was given medicine and directions on taking it, but none of the regular supervision the World Health Organization (WHO) deems necessary for effective treatment. Even worse, her children never received prophylactic medication or screening. Two of them, Jose, 10, and Fidencio, 14, developed what appeared to be tubercular growths on their faces and necks.
The family lives in a small yellow concrete building, topped with a corrugated roof and situated on a patch of dirt atop a hill. These claustrophobic, dusty conditions, exacerbated by chronic malnutrition among many indigenous children, are ideal for transmitting the TB bacteria.
"I felt very bad. Sometimes children do not get better. If you do not know how to take care of the children they die," said Gomez. "I know how to take care of them which is why I kept bringing them to the clinic." The children had surgery to remove the growths and are now okay.
All told, according to the WHO, TB infected an estimated 9.4 million people in 2008 and killed 1.8 million of them. Of particular concern, however, are the 150,000 who died that year of MDR and XDR strains of the disease.
In global terms, Mexico isn't the chief concern. Nearly two-thirds of all new multidrug-resistant tuberculosis cases are concentrated in Russia, China and India, according to an estimate by Dr. Salmaan Keshavjee of Harvard Medical School. TB experts are particularly concerned about China, where reliable infection data is hard to get. Another major breeding ground for virulent strains of TB is the former Soviet Union, particularly its prisons, where patients are jammed together in dank surroundings and receive poor medical care. Some poor regions there have the highest proportion of TB ever documented, with more than a quarter of new cases being drug-resistant.
Still, there were more than 21,000 new cases of TB in Mexico in 2007, and epidemiologist Dr. Hector Javier Sanchez-Perez estimates that in Chiapas, Mexico's poorest and most politically marginalized state, 14 percent of all TB cases are MDR TB -- nearly three times higher than the global proportion.
Mexican government statistics put the MDR TB rate in Chiapas at closer to 4 percent, but government health officials acknowledge they do not have comprehensive data, and do not discount the higher estimate. Sanchez-Perez contends that the federal government keeps the official rate of MDR TB low "because it is an indicator of the low level of human development. It's embarrassing."
The presence of the drug-resistant forms of the disease, in particular, is a sign that a health system is functioning badly. Patients on TB medication must take the entire cycle, which lasts six months. Because of the dangers of the disease developing into a tough, drug-resistant strain, patients are supposed to be closely monitored by health authorities to make sure they're following the drug regime.
But such labor-intensive treatment can be difficult in developing countries with limited resources. The primary reasons for the disease's spread in the last decade are the increase in poverty and the HIV/AIDS epidemic, which compromises the immune system and thus makes people more susceptible to the bug.
Mexico has made gains in public health at a national level, but poorer states like Chiapas still lag far behind, plagued by poverty, malnutrition, poorly trained doctors, insufficient labs and poor infection control in hospitals and prisons. "We know that a lot of infections are probably being transmitted to other patients and health care workers," Dr. McCray said.
"The problem with TB is that it is characterized as usually affecting indigenous, poor people, so we continue to marginalize it, and therefore its victims do not have a voice. That is the big problem," said Dr. Alied Bencomo, the new chief TB official in the region. "Anyone can get it, like me, not just the poor. That is the message we need to get out there."

http://www.aolnews.com/2010/07/01/us-health-officials-worry-about-tb-in-mexico/
http://vimeo.com/11923181

TUBERCULOSIS: Epidemiology and Surveillance of Tuberculosis in New Zealand

Epidemiology of tuberculosis
Recent tuberculosis (TB) notification rates in New Zealand have been around 10 per 100,000. Incidence has decreased slightly in recent years to around 7 per 100,000.
Higher rates of disease in New Zealand compared to other developed countries may be attributed to socioeconomic deprivation and immigration from high-incidence countries. Over two-thirds of all TB cases in New Zealand are in foreign-born individuals.
The highest rates of disease are seen in individuals in urban areas, particularly Auckland and South Auckland
of non-European ethnicity, particularly ‘Other’ and Pacific People.

Type, management and outcome of tuberculosis cases
Two-thirds of TB cases are pulmonary. Of the extra-pulmonary cases, the most common sites of infection are lymph nodes.
Morbidity and mortality from TB have been declining in recent years.
Multi-drug resistance occurs in less than 1% of all TB isolates.

Surveillance of tuberculosis
Surveillance is important for supporting the local management of TB, monitoring disease incidence and identifying risk factors.
A medical practitioner who diagnoses or suspects a case of new or relapsed TB must, under the Tuberculosis Act 1948, notify the case to the local medical officer of health.

It is not a legal requirement for clinicians to notify the local medical officer of health about people receiving treatment for latent TB infection. However, clinicians are asked to report cases to the local medical officer of health, for monitoring purposes, if the cases are of latent TB infection that are, or are recommended to be, under treatment.
Recent changes to surveillance include alterations to the TB case report form; the production of an annual surveillance report for TB (see the Public Health Surveillance website, http://www.surv.esr.cri.nz)

DNA fingerprinting of all isolates.
Recent improvements to the system include: laboratory notification of positive results to identify un-notified cases.

For the latest epidemiological information, see the Public Health Surveillance website (http://www.surv.esr.cri.nz/).
http://www.moh.govt.nz/moh.nsf/indexmh/tuberculosis-control-nz-guidelines-2010

TUBERCULOSIS: Tuberculosis: threatening Australia’s borders

Tony Radford, CEO of Cellestis. (Cellestis offers a solution to curb influx of tuberculosis brought in by immigrants and refugees.)

Tuberculosis (TB) is regarded by many as a disease of the past, but as a recent tuberculosis outbreak in Australian’s customs offices shows, there is a case for modernising testing for TB in developed nations, and Melbourne-based company Cellestis offers a way to do so.
The recent scare involving six Australian customs officials who appear to have contracted a latent tuberculosis infection has called into question the current protection and testing measures. The episode also highlights that while TB infection rates in Australia are relatively low – around 1000 new cases are reported per year – we remain exposed to real risks.
Additionally, a study released last year, following a review of Victorian health department data from 1998 to 2007, found there was an increase in the number of people who were diagnosed with MDR-TB, a mutant strain that is resistant to two of the most effective antibiotics used to treat TB. Even more dangerously, resistant strains of TB exist and are becoming more common around the world, and it can’t be ignored that this disease kills one person every 17 seconds worldwide.
This recent scare focuses our attention on TB in immigrants, and rightly so. In Australia, the chances of contracting TB from an Australian-born person are very low. The infection is mostly imported – because we make no effort to stop anything but the most developed cases from entering the country.
We allow people to enter the community carrying TB infection, possibly drug-resistant, in a manner that we would never consider allowable for any animal crossing our borders. Not even considering the rising number of boats arriving on our shores – 173 illegal boats since 2008 – even legal immigrants aren’t receiving the necessary TB testing to prevent a further outbreak of the highly infectious respiratory disease.
Tools which far more accurately detect TB infection and indicate who will develop TB are now available, rendering the old-fashioned mind-set that finding TB and treating it is too hard is simply that – old and out of date. This, coupled with the rising number of immigrants coming in from countries with a high rate of TB (Asia accounts for 55 per cent and Africa accounts for 30 per cent of all TB cases), are good reasons for Australian authorities to reconsider TB control. Demands need to be made for an overhaul and upgrade in the country’s testing and protection against the infectious disease.
Australia needs to step up its action plan against TB to match the global standard of disease management. The world-wide strategy is being led by the US, which this year released new guidelines recommending that the modern IGRAs (simple blood tests known as interferon-gamma release assays, like Cellestis’ QuantiFERON) are used to test for TB, and similarly endorsed their use in screening immigrants.
Other countries that have realised they need to take a tougher stance against TB include Ireland, which recently experienced an outbreak of TB in a primary school. With a usually low rate of TB – around 480 cases a year – the outbreak has caused the country to urgently review its testing and protection methods for the disease to prevent a reoccurrence. The clearly acknowledged fact is that some countries with low rates took their eye off the ball, and now, with rising TB rates they are paying the price. Australia is in a unique position with its geographical separation, and needs to develop and enact modernised TB control guidelines in immigration to prevent a similar situation occurring on our shores.
This is to the benefit of all. Latent TB carriers will be detected and will be treated before progressing to TB disease, it is clearly to their benefit. It is not expensive to diagnose or treat latent TB infection – it is expensive to wait and treat TB disease. The current immigrant testing protocol simply does not allow for testing and treating TB infection, but relies only on chest X-ray, which can only and inefficiently detect advanced disease, not latent infection.
Why is it so? X-ray can largely avoid the embarrassment of an immigrant immediately infecting others straight after arrival, but does little to stop importing the disease. But until Australians invented interferon testing, first for cattle TB, the only method to find TB infection was the tuberculin skin test, the TST or Mantoux test.
The TST is over 100 years old, extremely subjective to measure, and very frequently produces false positives. Such an unreliable test causes undue stress, and adds extra and unnecessary pressure on the health system and economy. Doctors are often uncomfortable prescribing treatment based on such a test, and this ‘do nothing’ mindset has permeated immigration testing. Customs workers are exposed on a daily basis to possible infection, and deserve better.
Cellestis’ QuanitFERON test (QFT) is scientifically proven to be six times more accurate than the TST – that is, six times fewer people need to be treated to stop the same amount of TB – and has demonstrated that the new test offered economic advantages of time saving through the elimination of producing false positives as with the TST tests.
It is clear that despite having the possibility of virtually eliminating TB in this country, saving money while showing a shining light to the world that a country can achieve this goal with a comparative modicum of effort and thought, Australia is lagging behind other nations. We have little control over TB infection coming into the country, and little to no guideline on interferon testing for TB infection.
The federal government in fact facilitates and subsidises the import and use of the TST reagents from the USA – where the US Centers for Disease Control and Prevention recommends use of QFT as beneficial in BCG (Bacillus Calmette-Guérin) vaccinated people, which is in fact common in immigrants and those most likely to have TB infection – to compete with this Australian product.
Cellestis’ has a declared an emphatic strategy to make latent TB diagnosis and treatment the paradigm in all countries. It makes solid health and economic sense. Current world TB-control strategies have had only limited success, and it’s clear that killing latent infection before it becomes a serious disease stops further spread – and if a test with high predictive capacity for future TB such as QuantiFERON is used, this will be achieved very economically.
The World Health Organisation has published reports clearly showing that only treatment of latent TB can make any significant impact on TB disease. The outcome of effective TB control is not only to save existing carriers but to cut the chain of transmission before the situation worsens.
The Stop TB Partnership, which gathered in early October to discuss a global plan to tackle TB, predicted that up to ten million people will die of the respiratory disease in the next five years. There is little cause to think it will go away in the world, and a lot of reason to worry about antibiotic resistant strains. Although only 1000 cases are reported in Australia each year, this number is set to rise if our borders are not protected with sufficient testing, and disease protection, for immigrants.

http://www.lifescientist.com.au/article/367368/opinion_tuberculosis_threatening_australia_borders/

TUBERCULOSIS: tuberculosis among Indigenous people in Australia

It is almost certain that Indigenous people did not suffer from tuberculosis prior to 1788 [3]. There was evidence of a high prevalence of TB among the first Europeans to arrive in Australia, however, and it is likely that the disease was soon transmitted to Indigenous peoples. There is little evidence of TB having a major impact on Indigenous people until around the middle of the 19th century, after which time it became the leading cause of death for those living in the more settled parts of the country [4]. For Indigenous people living in more remote parts of Australia, TB did not have a major impact until much later [5].

By the mid 20th century, the disease had spread to Indigenous communities in all parts of the country, but its impact was still somewhat variable [5]. The rate in the non-Indigenous population declined from the mid 20th century, partly due to a highly successful national TB campaign (1948-1976) [6]. The persisting impact of TB on Indigenous people has been attributed to the poor living conditions and malnutrition experienced by Indigenous people, compounded by chronic chest diseases and alcohol use [4] [7] [8].

Tuberculosis in recent years
TB is considered to be well under control in Australia with one of the lowest rates in the world. Notifications of TB among Aboriginal and Torres Strait Islander peoples have declined slightly, but they still remain much higher than those in the Australian born population [9].
There were 1,142 new cases of TB notified in 2006, but 969 (85%) of these were for people born outside Australia [9]. Of the 173 new cases involving people born in Australia, 33 (19%) were identified as Indigenous and 140 (81%) as non-Indigenous. The number of new cases of TB among Indigenous people in 2006 was slightly more than the number in 2005 (27), but less than those in previous years [10] [11] [12] [13].
In view of the relatively small numbers of cases and the year-to-year variations in numbers, the following comparison of TB incidence among Indigenous and non-Indigenous Australian-born people considers new cases for the five-year period, 2002-2006. In that period, there were 174 new cases of TB notified among Indigenous people and 711 among non-Indigenous Australian-born people [9] [10] [11] [12] [13]. Almost one-half of the new cases among Indigenous people were reported by the Northern Territory (83 cases) and around one-quarter by Queensland (45 cases) (Table 1). The Australia-wide crude incidence rate of 7.2 cases per 100,000 population for Indigenous people was almost 10 times the rate of 0.7 per 100,000 for non-Indigenous people. The crude incidence rate was highest for the NT (28 cases per 100,000 population).
This comparison underestimates the true difference between Indigenous and non-Indigenous people because of differences in the age structures of the Indigenous and non-Indigenous populations - after adjusting for these differences, the incidence rate for Indigenous people was 14 times that of non-Indigenous people (Table 2). The incidence of TB is higher for Indigenous people than for non-Indigenous people across all age groups, with rate ratios being highest for the 45-54 years and 55-64 years age groups.
http://www.healthinfonet.ecu.edu.au/infectious-conditions/tuberculosis/reviews/our-review

TUBERCULOSIS: USAID in Russia

Russia ranks 11th on the list of 22 high-burden tuberculosis (TB) countries in the world.

Image of a regional map of Asia with Russia highlighted.
After years of gradual decline, TB incidence doubled during the 1990s, but since 2000, the annual growth in the number of new cases has been smaller. According to the World Health Organization’s (WHO’s) Global Tuberculosis Control Report 2009, the TB incidence rate in 2007 was an estimated 110 new cases per 100,000 population, and an estimated one in five people have latent TB in Russia. Around 282,850 people died from TB between 1998 and 2007. Russia initiated DOTS (the internationally recommended strategy for TB control) in 1995, and population coverage has increased annually, reaching 45 percent by 2004 and 100 in 2007. Case detection remains low, particularly for sputum smear-positive (SS+) cases, though it increased from 15 percent in 2004 to 49 percent in 2007. Death, treatment failure, and default rates all continue to be high and contribute to low treatment success rate. Globally, Russia had the third largest number of multidrug-resistant (MDR) TB cases in 2007, with close to 43,000. Extensively drug-resistant (XDR) TB is a serious problem and may account for 6 percent of MDR-TB cases.1 The incidence of HIV, which complicates TB treatment, has also been growing again in recent years. In 2007, HIV co-infection among new TB cases was 16.3 percent.
Russia’s TB indicators reflect the slow progress following the collapse of the health care system after the breakup of the Soviet Union in the early 1990s. Russia was not able to sustain the previous TB infrastructure and this facilitated the spread of TB and MDR-TB. The country needed new approaches to TB control and although TB specialists and political officials (who favored the Soviet approach to TB control) initially resisted the DOTS approach, their acceptance progressed and continues to grow as the government looks for new solutions. Yet problems still remain. The case notification rate, which directly measures the capacity to detect cases of infectious TB, has revealed a very high proportion of SS - notifications among new cases. Support for supervision at the regional level is needed in order to ensure accurate implementation of the approved recommendations on TB control, particularly on MDR-TB treatment.
The approach to TB in prisons is improving, but remains complicated. MDR-TB and XDR-TB rates are high among prison inmates relative to other populations. The TB notification rate in the penitentiary system is approximately 17 times higher than in the civilian sector. DOTS is implemented in all prison health facilities, as most cases are diagnosed when inmates arrive at pre-trial detention facilities, and TB incidence, prevalence, and mortality in prisons are notably decreasing.

USAID Approach and Key Activities
USAID assistance in Russia began in 1998 with the objective of helping the government implement DOTS, reduce TB mortality, morbidity, and disease transmission. Through its partners, USAID has expanded DOTS, helped the Ministry of Health and Social Development (MOHSD) incorporate routine TB control into the health system, and provided training on internationally recognized TB diagnostics. USAID funding for TB programming in Russia totaled $7.1 million in fiscal year (FY) 2008. While this is a small percent of the total TB control program funding, it supports important interventions in target areas. Technical assistance (TA) focuses on nine target territories recommended by the MOHSD: Orel, Vladimir, Pskov, Belgorod, oblasts, Chuvashia Republic, Khakasia Republic, Republic of Adygeya (the North Caucasus region), Jewish Autonomous oblast and Khabarovsk kray (the Russian Far East). Two other territories recently started to receive limited TA (Orenburg and Mariy El). USAID activities have focused on the following:

Developing regional models for DOTS activities for MDR-TB and TB-HIV/AIDS
Increasing access to diagnosis and treatment for vulnerable populations
Strengthening TB control and disease surveillance in the general population, with interventions extending into the prison system; and establishing links between the civilian and prison health systems
Increasing civil society involvement in TB control efforts
Developing national- and provincial-level policies and training health care providers to understand DOTS
Strengthening laboratories as well as capacity building for program monitoring and supervision
Providing TA for improving infection control
Developing social and psychological support schemes for patients to improve adherence to treatment
Conducting operations research on TB control programs
USAID Program Achievements
USAID has played a major role in building political commitment in Russia for TB control and prevention based on the DOTS strategy. In partnership with WHO and others, USAID helped establish and support the High-Level Working Group on TB. At the program level, USAID support has expanded DOTS coverage to all of Russia’s territories. Achievements also include:
Implemented modern TB control systems in nine provinces, resulting in improved treatment success rates of up to 75 to 80 percent
Provided training in TB laboratory diagnostics, including smear microscopy, culture, and drug sensitivity testing (more than 700 laboratory personnel, including prison staff)
Supported and helped the Khakasia Republic TB laboratory become the highest ranked TB laboratory in proficiency testing nationwide
Improved infection control in six central province laboratories and provided equipment for 12 microbiological laboratories
Trained 2,297 health professionals in TB-related issues in FY 2007
Assisted the MOHSD in issuing new executive orders on TB diagnosis and treatment, recording and reporting systems, and prevention and treatment of HIV/AIDS-associated TB
Provided TA for the preparation of a proposal to the Global Fund to Fight AIDS, Tuberculosis and Malaria for TB control that was approved for $88 million
Provided treatment to 200 new MDR-TB patients in the Orel region in FY 2005–2007
Assisted five regions to obtain approval from WHO’s Green Light Committee (GLC) for DOTS-Plus treatment for MDR-TB for more than 5,400 patients in 2007
Established a Center of Excellence for TB and MDR-TB in FY 2007
Developed guidelines and training materials on the provision of TB care to people living with HIV/AIDS
Supported HIV testing for more than 90 percent of TB patients in USAID-assisted regions in FY 2007
Supported increased involvement of civil society in the fight against TB, including the more than 1,000 new Red Cross volunteers involved in TB control efforts in FY 2007
http://www.usaid.gov/our_work/global_health/id/tuberculosis/countries/eande/russia_profile.html

TUBERCULOSIS: Russia Bracing for Spread of Dangerous TB Strains

Sarah Schafer

 August 24, 2009
MOSCOW -- Russia's severe tuberculosis problem is about to get much worse, increasing the risk that the dangerous drug-resistant strains that are common here will spread, causing outbreaks elsewhere, local health officials and other experts warn.
Preliminary surveys have recorded an uptick in infections, which experts say could be the start of a surge fueled by declining living standards and deteriorating medical care resulting from the country's worst economic slowdown in a decade.
But Russian officials and health specialists also blame the government's failure to order supplies of key medicines last year, a blunder that could strengthen antibiotic-resistant forms of TB and threaten wealthier countries that have all but eradicated the disease.
Russia already has one of the highest rates of TB in the world. In parts of its Far East, the infection rate is three times what the World Health Organization considers epidemic levels. The government has made progress in recent years, with infection rates falling from a peak in 2000, but health officials are worried that those gains are now in jeopardy.
Preliminary state statistics show the rate of infection growing from 83.2 cases per 100,000 people in 2007 to 85.2 in 100,000 last year, and anecdotal evidence from hospitals and clinics around the country suggests that the numbers are still climbing.
By comparison, the infection rate in the United States is about 8 in 100,000, with about 0.2 percent of American TB cases ending in death. In Russia, about 18 percent of TB patients die of the disease, according to WHO figures.
"Because people are poorer and life is worse, the disease is progressing much faster now," said Veronika Agapova, a tuberculosis specialist with the Russian Red Cross. "The Ministry of Health didn't pay a lot of attention to this problem last year," she added.
Although the increase reported was small, officials are worried because the number of TB cases soared the last time Russia suffered a severe economic downturn, rising from 74 cases per 100,000 people before the 1998 financial crisis to 90.4 two years later.
"What was bad in 2008 will continue to be seen in 2009 and 2010," said Mikhail Perelman, Russia's most prominent TB specialist. "I am pessimistic. . . . The WHO set a goal to eradicate tuberculosis, but this task seems quite fantastic to us at this point."
A spike in infections in Russia could have consequences well beyond its borders because about a fifth of all TB patients here suffer from drug-resistant strains -- more than almost anywhere else in the world.
In 2006, a Russian-born man infected with a strain of drug-resistant TB was jailed after moving to Arizona and ignoring a judge's order to wear a mask outdoors. A year later, an American lawyer with drug-resistant TB set off an international panic and was quarantined after traveling across Europe and returning to the United States.
"Like air pollution, it doesn't see a border," said Murray Feshbach, an expert on Russian public health at the Woodrow Wilson International Center for Scholars who argues that Russia understates its TB rate by as much as 50 percent.
http://www.washingtonpost.com/wp-dyn/content/article/2009/08/23/AR2009082302208.html

Friday, 17 December 2010

TUBERCULOSIS: History: Tuberculosis in the Royal Norwegian Navy during the war

A Ongre J Sommerfelt-Pettersen
Tuberculosis became a great problem in the Royal Norwegian Navy during the first years of the Second World War (when it operated in allied services mainly from Great Britain); with the highest incidence (9.6 per 1 000) during the first half of 1943. Main reasons were insufficient medical examination of recruits, crowded living conditions on board (favoured the contagion) and the physical and psychological pressure during sea operations, which may have reduced the immune defence.
Preventive measures in terms of tuberculin testing, chest X-rays of the positives, vaccination of the negatives, environment investigation when disease was discovered, and isolation of those infected, gave control from the second half of 1943 and onwards.
The article also mentions treatment, repatriation and the incidence of tuberculosis in the Navy before and after the war.
The tuberculosis situation is currently so favourable in Norway that routine chest X-ray of the recruits is no longer performed in the armed forces.



During the war, the Government in exile established a chain of clinics for seamen on both sides of the Atlantic. Their mandate was to prevent and treat illness amongst seamen and to inspect Norwegian ships. In addition, they were given an advisory role towards the authorities. Illustrative photograph © courtesy of the Bergen Maritime Museum

In June 1940, the Norwegian Navy had 16 vessels, with approximately 600 men, stationed in Great Britain under Norwegian command. The Navy had suffered heavy losses during the military actions in Norway, and needed rebuilding and remanning virtually from scratch. By the summer of 1940 naval vessels had entered service in British waters. The number of naval servicemen increased considerably during the next years, and the Navy became the largest branch of the Norwegian armed forces in England during the war. By the end of the war, in 1945, there were 52 vessels with a personnel strength of 7 366 (1).
However, the large growth did not come without costs. A report (released in 1943) on treated active tuberculosis in the armed forces, showed that the Navy had far more cases of tuberculosis than the other branches of the Forces (2). In the Navy, 125 people had been treated for active tuberculosis.
This was a prevalence vastly exceeding that which would have been expected in Norway, and corresponded to a prevalence not seen in over 10 years in the Navy. We do not know the incidence of tuberculosis (TB) in the Royal Norwegian Navy in the years immediately preceding the war; the last health statistics available before the outbreak of war were from the years 1931 and 1935 (3). The incidence rate of tuberculosis showed a significant decrease in this period, from 10 in 1931 to approximately three only four years later (tab 1) (3, 4). There was a corresponding drastic decline in TB morbidity, which had been very high in the years after the Spanish influenza epidemic (5).
Tuberculosis caused a large number of lost workdays during the war. Johannes Kvittingen (1906–1996) & Nils Bonsaksen (1917–73), who served in the Navy during the war, has provided this documentation which is based on a number of Norwegian archives from Great Britain, Iceland and Canada, as well as reports and announcements from the British medical corps (6). Altogether 237 new cases of tuberculosis were detected during the war years, but the distribution between servicemen based on land and at sea is unclear.

Reasons for a high prevalence in the Navy during the war
It has been postulated that the most important reason for the high incidence of TB infections was that the Navy was built up without making proper provisions for a comprehensive and effective naval medical corps. Not all measures for prevention of contagion coming into the Navy were exhausted (6).
The military services had a large personnel requirement, and men occasionally entered service without prior medical examination. Moreover, the criteria for fitness for service became markedly lower than in the pre-war period. It may be assumed that tuberculosis slipped into the armed services when volunteers were recruited (6).
The Lofoten Island raids exemplify this shift of paradigm, for amongst others Anders Chr. Gogstad. He writes: «Bemerkelsesverdig var at alle menn som kom fra Lofoten etter raidene der i 1941 ble fordelt på hær og marine uten forutgående legeundersøkelser. De fleste av disse kom til Marinen og medførte smittekilder» (It was noteworthy that all men who came back from the Lofoten Islands after the raids in 1941 were recruited to the Army and Navy without prior medical examination. The majority of them entered the Navy and included carriers») (7). The first Lofoten raid, «Operation Claymore», took place in the beginning of March 1941. On the return from the Lofoten Islands the ships were willing to take on board anyone who freely chose to go to Great Britain and join the Norwegian armed forces; 306 men and 8 women enlisted (1). The second Lofoton raid, «Operation Anklet», was conducted at the end of December 1941. Altogether 266 Norwegians came to Great Britain with this raid. Additionally, families with children also fled, for fear of reprisals, such as those who had helped the soldiers during the first raid had been subjected to.
We agree that an important reason for the increase in tuberculosis during he first years of the war were the reduced fitness requirements for entering military service and the inadequate screening of new recruits resulting from the urgent increase in recruitment needs. However, the first group who returned with the first Lofoton raid were, in fact, screened for tuberculosis (normal X-ray examination and X-ray screen photography). The screening was part of a research project, but was not comprehensive; the clinical examination before X-ray screen photography did not include sedimentation rate or TB testing. The Norwegian radiologist Kaare Tutein Poulsson (1904–67), who had escaped to Great Britain in February 1941, took part in a study where X-ray screen photography was compared to conventional chest X-ray examination (8, 9). The patient sample consisted of Norwegians who had come to London during the previous 3 months to join the armed forces and included amongst others «the group of men who had escaped from the Lofoten Islands during March 1941». No tuberculosis was found in this group. The TB carriers from the Lofoten Islands presumably came over with the second raid. Kvittingen & Bonsaksen report that the volunteers who came over with the Lofoten raid of January 1941 were not examined, however this cannot be correct and is presumably a textual error, as Kvittingen was one of the referring physicians while Gogstad could hardly have known about X-ray screen photography.
In addition to inadequate medical examination of new recruits, the cramped living conditions and enormous pressure during active service were fundamental factors behind the increase in the prevalence of tuberculosis. A person coming on board with contagious tuberculosis could easily cause an epidemic. The crew were very tightly quartered on the dark orloft deck (i.e. quarters for enlisted men beneath the main deck) and worked, ate and slept very close to one another. In those days men slept in hammocks that were rolled up and stored in communal bins during daytime. The service could be extremely demanding. Storms, ice, torpedo attacks, frequent sounding of «battle stations», lack of sleep, wet clothes that never dried properly and the primitive sanitary conditions were the daily stock in trade when at sea. Folke Hauger Johannesen, later admiral and general officer, writes the following in his memoirs: «Det var ikke underlig at tuberkulosen krevde offer» (It is not surprising that tuberculosis claimed its victims) (10). He was captain of the destroyer «St. Albans» in 1943 when 10 cases of tuberculosis were reported, of which nine came from the same lower deck (2).
Preventive measures
The Navy had previously maintained an extensive programme of preventive measures against tuberculosis. In 1920 a specialised medical examination of all recruits directed at preventing tuberculosis carriers from entering service was introduced in both the Army and the Navy (11). From 1922 and onwards, all recruits at Horten were examined by X-ray if there were suspicious findings from the clinical examination or the recruit’s medical history, and if necessary admitted to the naval hospital at Karljohansvern «and injected with increasing doses of Koch’s tuberculinum vetus». An X-ray screen photography apparatus was acquired before 1940 (12).
Preventive examinations were given lower priority during the first years of the war, due to the enormous resources demanded by rebuilding the Navy. When it was established, in January 1941, that there had been an increase of the TB incidence, the military medical corps gave orders and laid plans for a battle against tuberculosis in all branches of the armed forces (6). There was not much to do about the cramped living conditions that increased the risk of contagion on board ships, nor could one change the physical and psychological pressures of war, which could weaken the immune defences. However, one could prevent contagion from coming on board ships. The decision was taken that all naval personnel would be examined with Pirquet’s test, all positives would undergo X-ray examinations, and all negatives would be given the BCG vaccination. Environmental investigations were to be undertaken in locations where new cases were detected. Those infected were to be placed in isolation to prevent the disease from spreading. With these preventative measures the disease was brought under control from 1943 onwards, and the incidence in the last half year of the war was the same as in the autumn of 1940. The introduction of systematic examinations aimed at tuberculosis was not, however, unique to the Navy. The war against tuberculosis was also fought back home in Norway. Sophus W. Brochmann (1892–1956) introduced mass X-ray screening of the population in 1943. Brochmann was the inspector for tuberculosis under the Nazi regimen and had taken over the plans of the deposed Otto Galtung (1904–81). This took place under the surveillance of the health department of the German «Reichskommissar» in Norway (national commissioner), and the programme was approved as an independent Norwegian venture (13).

Tuberculosis in the Canadian Navy
The Royal Canadian Navy was in many respects similar to the Norwegian Navy and thus serves as an interesting basis for comparison with regard to prevalence and prevention of tuberculosis. Over 40 % of the Canadian personnel served on ships, primarily on destroyers and smaller ships on escort duty under the same stressful conditions as parts of our Navy (14, 15). All men assigned to service on board underwent an X-ray examination before embarkation, and annual X-ray examinations of all personnel was intended though this was not entirely successful. During the war years the annual personnel strength increased from 27 614 to 99 078. Altogether 490 cases of tuberculosis were diagnosed with an annual average incidence of 2.36 per 1 000. In our small Navy there were 247 cases. The relatively low number of TB sufferers can primarily be explained by thorough examination of recruits, which prevented the intake of carriers.

Treatment and follow-up of tuberculosis patients
Towards the end of 1941 the Norwegian authorities were able to rent a part of Craiglockhart, which was a nursing home in Edinburgh that had been expropriated and turned into the «Emergency Health Service» in 1939. A hospital with 145 beds and a Norwegian staff was subsequently established and equipped (16). Hans Gabriel Dedichen (1901–81), who came to England in February 1942, took over the management of Craiglockhart hospital in January 1942 (8, 17). All Norwegians who contracted tuberculosis in Great Britain were referred there. During the three and a half years the hospital was in service, 988 TB patients were admitted, and of these 32 died. The archives from Craiglockhart show that children with home addresses in Lofoten had also been admitted to this institution; they must have come to Great Britain with the second raid (18). Altogether 479 thoracic interventions were performed. Many patients were cured, but with few exceptions none from the Navy were allowed to return to duty either at sea or on land.
During the time in Great Britain the Norwegian Navy were not allowed to discharge patients who were cured, and consequently accumulated a large number of absentee days because of tuberculosis; in total 98 326. Several convalescence homes were established for TB patients. It was difficult to find suitable employment for the convalescents who subsequently became a significant expense for the Norwegian military health authorities.



The Norwegian Navy in rough weather in the arctic sea: after-deck with depth charges. Illustrative photograph© courtesy of the Naval Museum

Repatriation of TB patients after the declaration of peace presented transportation problems. Some of the Navy’s patients in Scotland who were bacillus negative, were transported home by naval vessels (2). On the basis of a proposal from Dedichen, in his letter of 13 May 1945, it was decided that patients and personnel from Craighlockhart and convalescence homes in the Newlands and Brocklehurst should be transported together along with the archives from the individual institutions (16). The passenger-liner «Stavangerfjord» received the assignment and arrived in Oslo at the end of August 1945. The newspaper Arbeiderbladet referred to the unusual passengers brought home by the America Lines legendary ship with the following headline, «En broget last: Fra arresterte Quislinger til barn som skal døpes.- Overlege Dedichen hjem med alle sine pasienter» (A varied cargo: from arrested Quislings to children about to be baptised– Dr Dedichen home with all his patients). 14–15 of them were so unwell that they had to be carried on stretchers from the ship and driven directly to Berg hospital, which was a temporary hospital for evacuees at Berg school in Oslo (19). We have identified 24 report cards in the archives from the evacuation hospitals at Berg and Grefsen, which almost certainly refer to TB patients from the Navy (20).
TB patients also had to be transported home from America. Plans were laid for the repatriation of approximately 200 TB patients, of which 100 would require a stay in a sanatorium (16). They were received by Berg hospital for evacuees in October 1945, where they held an «emotional welcome home party for the sick seamen» (21). We know little about the fate of the TB patients after repatriation.

Tuberculosis in the Armed Forces immediately after the war
After demobilisation 1 January 1946, the BCG vaccination of Pirquet test negatives was no longer mandatory. The law of 12 December 1947 was passed, tuberculin testing and vaccination of individuals or groups stated that Pirquet testing and vaccination could be made mandatory for individuals or groups. BCG vaccination did not become mandatory for all military personnel before October 1950. While the number of TB cases decreased in other branches of the armed forces it remained high in the Navy. Amongst other causes, there was an epidemic in 1947 where the carrier was probably an asymptomatic recruit. Cavernous lung tuberculosis was observed on X-Ray screen photography during the screening medical examination, but because the report was mislaid the result was not received before the recruit fell ill. By this time he had managed to infect many of his fellow recruits. By the time the environmental investigations were finally conducted, the men had already been sent to several different military locations, and amongst 221 servicemen, 65 with signs of TB infection were found.
The incidence of tuberculosis remained high in the Armed Forces in 1948 (23). The majority were in the Navy (prevalence 11.9); with a significantly higher prevalence than in the air force (4.5), in the army (3.9) and amongst civilian men in Oslo from the same age group (3.5). A reason for this may be that a larger proportion of the naval recruits came from the most tuberculosis ravaged coastal districts than those recruited to other branches of the armed forces (23). There were four times as many cases of tuberculosis in previously tuberculin negative individuals as in the air force or the army. Cramped living conditions could explain the increased risk of infection, also of other infectious diseases, which could conceivably reduce resistance to tuberculosis.
This negative spiral continued in the Navy. From 1949 to 1952 tuberculosis morbidity showed a marked decline among the enlisted men in the armed forces with the exception of the Navy (24, 25). While the incidence of destructive tuberculosis decreased significantly, from 18 to 6 per 10 000 between 1949 and 1952 in the armed forces as a whole, it still remained at roughly the same level in the Navy even in 1952. TB morbidity among the junior and non-commissioned officers does not show the same differences between the branches of the armed services.
The situation today
Hygienic conditions on ships have been significantly improved since wartime, but cramped living conditions seem unavoidable. The naval medical corps is alert to the fact that tuberculosis is on the increase in many places around the world, with resistant strains of the bacillus being an additional problem. More recruits are tuberculin negative now that the BCG vaccination is no longer mandatory. The naval doctor looks for vaccination scars in all who are drafted into the military service for the first time, and assesses whether referral is necessary for X-Ray examination of the lungs. BCG vaccine should be given to all personnel working on board ships or cleared for international duty who have no sign of a BCG vaccination scar, no documented vaccination, and a negative Mantoux reaction. All personnel coming home from international service are obliged to undergo a medical check up for monitoring and follow-up of tuberculosis.
The following quote, from a lecture given by Alexander Tuxen (1897–1980) in 1966, remains relevant today: «En vakker dag kommer folkemassene, folkehavene i bevegelse, og de har tuberkulosen med seg. En vakker dag, på en eller annen måte kommer tuberkelbasillen igjen hvis vi ikke passer på den» (Some day the masses will come, a sea of migrating people, and they will bring tuberculosis with them. If we become unvigilant, the tuberculosis bacillus will return one way or the other) (26).

http://www.tidsskriftet.no/index.php?seks_id_eng=34270&seks_id=1784479